Generics in the United Kingdom
Published: August 2013 · Publisher: MarketLine
Generics in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Generics in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United Kingdom generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The UK generics market had total revenues of $6.3bn in 2012, representing a compound annual growth rate (CAGR) of 6.9% between 2008 and 2012.
*Market consumption volume increased with a CAGR of 3.1% between 2008-2012, to reach a total of 73.5% of total pharma volume in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.6% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $7.9bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the United Kingdom
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United Kingdom
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the United Kingdom economy
Key Questions Answered
What was the size of the United Kingdom generics market by value in 2012?
What will be the size of the United Kingdom generics market in 2017?
What factors are affecting the strength of competition in the United Kingdom generics market?
How has the market performed over the last five years?
What are the main segments that make up the United Kingdom's generics market?
Generics in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United Kingdom generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The UK generics market had total revenues of $6.3bn in 2012, representing a compound annual growth rate (CAGR) of 6.9% between 2008 and 2012.
*Market consumption volume increased with a CAGR of 3.1% between 2008-2012, to reach a total of 73.5% of total pharma volume in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.6% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $7.9bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the United Kingdom
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United Kingdom
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the United Kingdom economy
Key Questions Answered
What was the size of the United Kingdom generics market by value in 2012?
What will be the size of the United Kingdom generics market in 2017?
What factors are affecting the strength of competition in the United Kingdom generics market?
How has the market performed over the last five years?
What are the main segments that make up the United Kingdom's generics market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Bayer AG, Mylan Inc., Sandoz International GmbH and Sanofi
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market volume 10
Market Segmentation 11
Geography segmentation 11
Market Outlook 12
Market value forecast 12
Market volume forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Bayer AG 20
Mylan Inc. 24
Sandoz International GmbH 27
Sanofi 28
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related research 34
LIST OF TABLES
Table 1: United Kingdom generics market value: $ million, 2008–12 9
Table 2: United Kingdom generics market volume: % of total pharma volume, 2008–12 10
Table 3: United Kingdom generics market geography segmentation: $ million, 2012 11
Table 4: United Kingdom generics market value forecast: $ million, 2012–17 12
Table 5: United Kingdom generics market volume forecast: % of total pharma volume, 2012–17 13
Table 6: Bayer AG: key facts 20
Table 7: Bayer AG: key financials ($) 21
Table 8: Bayer AG: key financials (€) 21
Table 9: Bayer AG: key financial ratios 22
Table 10: Mylan Inc.: key facts 24
Table 11: Mylan Inc.: key financials ($) 24
Table 12: Mylan Inc.: key financial ratios 25
Table 13: Sandoz International GmbH: key facts 27
Table 14: Sanofi: key facts 28
Table 15: Sanofi: key financials ($) 29
Table 16: Sanofi: key financials (€) 29
Table 17: Sanofi: key financial ratios 29
Table 18: United Kingdom size of population (million), 2008–12 31
Table 19: United Kingdom gdp (constant 2000 prices, $ billion), 2008–12 31
Table 20: United Kingdom gdp (current prices, $ billion), 2008–12 31
Table 21: United Kingdom inflation, 2008–12 32
Table 22: United Kingdom consumer price index (absolute), 2008–12 32
Table 23: United Kingdom exchange rate, 2008–12 32
LIST OF FIGURES
Figure 1: United Kingdom generics market value: $ million, 2008–12 9
Figure 2: United Kingdom generics market volume: % of total pharma volume, 2008–12 10
Figure 3: United Kingdom generics market geography segmentation: % share, by value, 2012 11
Figure 4: United Kingdom generics market value forecast: $ million, 2012–17 12
Figure 5: United Kingdom generics market volume forecast: % of total pharma volume, 2012–17 13
Figure 6: Forces driving competition in the generics market in the United Kingdom, 2012 14
Figure 7: Drivers of buyer power in the generics market in the United Kingdom, 2012 15
Figure 8: Drivers of supplier power in the generics market in the United Kingdom, 2012 16
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2012 17
Figure 10: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2012 18
Figure 11: Drivers of degree of rivalry in the generics market in the United Kingdom, 2012 19
Figure 12: Bayer AG: revenues & profitability 22
Figure 13: Bayer AG: assets & liabilities 23
Figure 14: Mylan Inc.: revenues & profitability 25
Figure 15: Mylan Inc.: assets & liabilities 26
Figure 16: Sanofi: revenues & profitability 30
Figure 17: Sanofi: assets & liabilities 30
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market volume 10
Market Segmentation 11
Geography segmentation 11
Market Outlook 12
Market value forecast 12
Market volume forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Bayer AG 20
Mylan Inc. 24
Sandoz International GmbH 27
Sanofi 28
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related research 34
LIST OF TABLES
Table 1: United Kingdom generics market value: $ million, 2008–12 9
Table 2: United Kingdom generics market volume: % of total pharma volume, 2008–12 10
Table 3: United Kingdom generics market geography segmentation: $ million, 2012 11
Table 4: United Kingdom generics market value forecast: $ million, 2012–17 12
Table 5: United Kingdom generics market volume forecast: % of total pharma volume, 2012–17 13
Table 6: Bayer AG: key facts 20
Table 7: Bayer AG: key financials ($) 21
Table 8: Bayer AG: key financials (€) 21
Table 9: Bayer AG: key financial ratios 22
Table 10: Mylan Inc.: key facts 24
Table 11: Mylan Inc.: key financials ($) 24
Table 12: Mylan Inc.: key financial ratios 25
Table 13: Sandoz International GmbH: key facts 27
Table 14: Sanofi: key facts 28
Table 15: Sanofi: key financials ($) 29
Table 16: Sanofi: key financials (€) 29
Table 17: Sanofi: key financial ratios 29
Table 18: United Kingdom size of population (million), 2008–12 31
Table 19: United Kingdom gdp (constant 2000 prices, $ billion), 2008–12 31
Table 20: United Kingdom gdp (current prices, $ billion), 2008–12 31
Table 21: United Kingdom inflation, 2008–12 32
Table 22: United Kingdom consumer price index (absolute), 2008–12 32
Table 23: United Kingdom exchange rate, 2008–12 32
LIST OF FIGURES
Figure 1: United Kingdom generics market value: $ million, 2008–12 9
Figure 2: United Kingdom generics market volume: % of total pharma volume, 2008–12 10
Figure 3: United Kingdom generics market geography segmentation: % share, by value, 2012 11
Figure 4: United Kingdom generics market value forecast: $ million, 2012–17 12
Figure 5: United Kingdom generics market volume forecast: % of total pharma volume, 2012–17 13
Figure 6: Forces driving competition in the generics market in the United Kingdom, 2012 14
Figure 7: Drivers of buyer power in the generics market in the United Kingdom, 2012 15
Figure 8: Drivers of supplier power in the generics market in the United Kingdom, 2012 16
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2012 17
Figure 10: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2012 18
Figure 11: Drivers of degree of rivalry in the generics market in the United Kingdom, 2012 19
Figure 12: Bayer AG: revenues & profitability 22
Figure 13: Bayer AG: assets & liabilities 23
Figure 14: Mylan Inc.: revenues & profitability 25
Figure 15: Mylan Inc.: assets & liabilities 26
Figure 16: Sanofi: revenues & profitability 30
Figure 17: Sanofi: assets & liabilities 30
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.